申请人:Aventis Pharma Limited
公开号:EP2233486A1
公开(公告)日:2010-09-29
The invention is directed to compounds of general formula (I):-
and pharmaceutically acceptable salts and solvates of such compounds. Such compounds have valuable pharmaceutical properties, in particular the ability to inhibit kinases.
本发明涉及通式(I)如下的化合物
以及这类化合物的药学上可接受的盐和溶液。此类化合物具有宝贵的药用特性,尤其是抑制激酶的能力。